References
- Arzumanyan A, Reis HM, Feitelson MA (2013). Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer, 13, 123-35. https://doi.org/10.1038/nrc3449
- Bruix J, Sherman M (2011). Management of hepatocellular carcinoma: an update. Hepatol, 53, 1020-2. https://doi.org/10.1002/hep.24199
- Hongthanakorn C, Chotiyaputta W, Oberhelman K, et al (2011). Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos (t)ide analogues in clinical practice. Hepatol, 53, 1854-63. https://doi.org/10.1002/hep.24318
- Huang H, Li X, Zhu J, et al (2014). Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial. JAMA, 312, 2521-30. https://doi.org/10.1001/jama.2014.15704
- Jang JW, Choi JY, Bae SH, et al (2004). Transarterial chemolipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma. J Hepatol, 41, 427-35. https://doi.org/10.1016/j.jhep.2004.05.014
- Jang JW, Choi JY, Bae SH, et al (2006). A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology, 43, 233-40. https://doi.org/10.1002/hep.21024
- Jang JW, Kwon JH, You CR, et al (2011). Risk of HBV reactivation according to viral status and treatment intensity in patients with hepatocellular carcinoma. Antivir Ther, 16, 969-77. https://doi.org/10.3851/IMP1840
- Kim IK, Kim BG, Kim W, et al (2012). Clinical prediction of failure of Lamivudine prophylaxis for hepatitis B virusinfected patients undergoing cytotoxic chemotherapy for malignancy. Antimicrob Agents Chemother, 56, 5511-9. https://doi.org/10.1128/AAC.00821-12
- Li X, Lin Q, Dong M, et al (2010). Prognostic analysis of acute exacerbations of hepatitis-B after chemotherapy in combination with rituximab in 19 patients with lymphoma. Leuk Lymphoma, 51, 1678-85. https://doi.org/10.3109/10428194.2010.499486
- Li X, Xing YF, Lin Q, et al (2012). The treatment of severe hepatitis B virus reactivation after chemotherapy. Nat Rev Clin Oncol, 9, 350.
- Li X, Zhong X, Chen ZH, et al (2014). Hepatitis B virus DNA negativity acts as a favorable prognostic factor in hepatocellular carcinoma patients. Asian Pac J Cancer Prev, 15, 9635-41. https://doi.org/10.7314/APJCP.2014.15.22.9635
- Liver EAftSot (2012). EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol, 57, 167-85. https://doi.org/10.1016/j.jhep.2012.02.010
- Lok AS, McMahon BJ (2007). Chronic hepatitis B. Hepatol, 45, 507-39. https://doi.org/10.1002/hep.21513
- Lok AS, McMahon BJ (2009). Chronic hepatitis B: update 2009. Hepatol, 50, 661-2. https://doi.org/10.1002/hep.23190
- McMahon BJ (2009). The natural history of chronic hepatitis B virus infection. Hepatol, 49, 45-55. https://doi.org/10.1002/hep.22898
- Nagamatsu H, Itano S, Nagaoka S, et al (2004). Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy. Am J Gastroenterol, 99, 2369-75. https://doi.org/10.1111/j.1572-0241.2004.40069.x
- Park JW, Park KW, Cho SH, et al (2005). Risk of hepatitis B exacerbation is low after transcatheter arterial chemoembolization therapy for patients with HBV-related hepatocellular carcinoma: report of a prospective study. Am J Gastroenterol, 100, 2194-200. https://doi.org/10.1111/j.1572-0241.2005.00232.x
- Peng JW, Lin GN, Xiao JJ, et al (2012). Hepatitis B virus reactivation in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization therapy. Asia Pac J Clin Oncol, 8, 356-61. https://doi.org/10.1111/j.1743-7563.2012.01534.x
- Torres HA, Davila M (2012). Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol, 9, 156-66. https://doi.org/10.1038/nrclinonc.2012.1
- Vizzini GB, Luca A, Marino IR (2003). Hepatitis B virus reactivation after a single session of transarterial chemoembolization in patients with hepatocellular carcinoma. Ann Intern Med, 138, 691-2.
- Wu XY, Li X, Chen ZH, et al (2013). An optimized antiviral modification strategy for prevention of hepatitis B reactivation in patients undergoing prophylactic lamivudine and chemotherapy: a pilot study. Tumour Biol, 34, 909-18. https://doi.org/10.1007/s13277-012-0626-6
- Yeo W, Chan HL (2013). Hepatitis B virus reactivation associated with anti-neoplastic therapy. J Gastroenterol Hepatol, 28, 31-7. https://doi.org/10.1111/j.1440-1746.2012.07280.x
- Zhong S, Yeo W, Schroder C, et al (2004). High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy. J Viral Hepat, 11, 55-9. https://doi.org/10.1046/j.1352-0504.2003.00467.x
- Ziakas PD, Karsaliakos P, Mylonakis E (2009). Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. Haematologica, 94, 998-1005. https://doi.org/10.3324/haematol.2009.005819
Cited by
- Changes of HBV DNA After Chemoembolization for Hepatocellular Carcinoma and the Efficacy of Antiviral Treatment vol.61, pp.9, 2016, https://doi.org/10.1007/s10620-016-4167-5
- Current clinical evidence for nucleos(t)ide analogues in patients with HBV-related hepatocellular carcinoma vol.11, pp.10, 2017, https://doi.org/10.1080/17474124.2017.1343665